A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Trial Profile

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Vilazodone (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan; Forest Laboratories
  • Most Recent Events

    • 06 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Feb 2015 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top